Jennifer Michaelson - Jul 5, 2024 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Jul 5, 2024
Transactions value $
-$130,640
Form type
4
Date filed
7/9/2024, 05:30 PM
Previous filing
Jul 2, 2024
Next filing
Sep 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Sale -$131K -8K -6.06% $16.33 124K Jul 5, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.97 to $16.77. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.